{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.69","upperLimit":"5.52","value":"2.73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were accrued at 50 mg/m\\^2 dose level after December 30, 2009 addendum. Participants to receive 50 mg/m\\^2 dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Phase II"}],"paramType":"MEDIAN","populationDescription":"All 15 evaluable participants were analyzed for Progression-Free Survival.","reportingStatus":"POSTED","timeFrame":"Time from registration to progression or death due to any cause, assessed up to 3 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}